Novo Nordisk Pump Priming Guidelines
Novo Nordisk and the University of Oxford have a long-standing relationship and a shared interest to undertake translational research in the field of cardiometabolic disease and drug discovery for metabolic disorders. To facilitate a deeper co-operation and a closer collaborative environment pump priming awards will be made available.
In January 2017, the University of Oxford and Novo Nordisk announced a landmark research collaboration. As part of the collaboration, Novo Nordisk has built a research centre within the University of Oxford: The Novo Nordisk Research Centre Oxford (NNRCO). The centre focuses on innovation within early stage research that has the potential to substantially impact future treatment of cardiometabolic disease. NNRCO is located within the Innovation building on Old Road Campus.
Areas of Interest
It is expected that these projects will be codeveloped and should have relevance to understanding human cardiometabolic biology and disease. Priority will be given to projects aligned with NNRCO’s areas of interest, such as human genetics, human cellular disease models, functional genomics, multi-omics, high content imaging, phenotypic screens and computational biology. Due to the collaborative nature of the project, it is expected that either party could bring expertise covering one or more of these areas of interest. Applications should describe the translational potential of projects, such as the use of human-relevant tissues and assays, and how results will help elucidate cardiometabolic disease mechanisms and potentially identify targets.
It is expected that most pump priming research will be precompetitive and that any arising IP would be joint (Subject to contract & 3rd party funders if present).
Projects with a maximum cost of up to £35k each will be considered for funding, the projects should be undertaken within 12 months.
The funds are provided from Novo Nordisk and can cover consumables, expenses, analysis costs, animal costs, other services, travel and personnel costs at University of Oxford, but not that of a new hire.
Pump Priming Awards will be made in alignment with the pre-agreed and pre-approved Strategic Alliance Agreement, which covers Intellectual Property (IP) rights and publication procedures.
- All applications, information provided and discussions should be non-confidential
- IP will be jointly owned
- Written proposals for publication will be submitted to Novo Nordisk 45 days prior to publication (however, reviews will be undertaken as quick as possible)
- If you have questions relating to disclosure of background Intellectual Property relating to this proposal, [that you believe may need to be protected], please seek advice from OUI Life Sciences (firstname.lastname@example.org)
Only a simple letter of agreement, aligning with the Strategic Alliance Agreement will be required if successful.
- Proposals must be new and should not have been submitted in a substantial form to other granting bodies, professional or lay.
- All applications must include both researchers from the University of Oxford and Novo Nordisk Research Centre Oxford. Any University of Oxford researcher can apply for these funds.
- Projects already funded by another industry partner are ineligible.
- It is recommended that successful applicants do not re apply within 2 years and the lead applicant must have a funded position at the University of Oxford for the duration of their proposed project.
- University of Oxford academics should not submit more than two applications per round (as lead PI)
- Only required personnel should be named as applicants.
- University of Oxford applicants should discuss with their departmental administrator all proposals, as they will provide an X5 costing for the funding you require. Although X5 costings are not required to be (and should not be) attached to an application an X5 should still be done and approved by your administrator prior to application, please give 5 working days for your administrator to do this.
- All costings should be performed at 100% FEC – please contact Liz Covey-Crump should you or your administrator have any questions.
All applicants must align with a Novo Nordisk Research Centre Oxford staff prior to application, this should be done by 19th May 2022 at the latest.
Please submit your application online via the Internal Research Award Management System (IRAMS). The award can be found under the title Novo Nordisk Oxford Pump Priming Award.
Oxford University applicants should discuss with their departmental administrator all proposals, as they will provide an X5 costing for the funding you require. Although X5 costings are not required to be (and should not be) attached to an application an X5 should still be done and approved by your administrator prior to application. All costings should be performed at 100% FEC – please contact Liz Covey-Crump should you or your administrator have any questions.
Feedback is intended to be provided from the Novo Nordisk Oxford Collaboration Committee at a maximum of 1 month after the call deadline and the goal is to have the projects initiated at a maximum of 3 months after the call deadline, e.g. with a 1st October 2022 start date.
All successful applicants will be expected to be available for review during the collaboration and to write a short end-of-project report, within 3 months of the end of the 12 month (maximum) project.
Deadline: Monday 6 June 2022, 12.00 pm
Please ensure that you have contacted either Dorthe Lundsgaard (Senior Alliance Manager - Novo Nordisk) or Liz Covey-Crump by at the latest Thursday 19 May to allow time to discuss a potential project with NNRCO scientific collaborators.
Applications are via IRAMs and time should be given to obtain an X5 (required prior to application, but not to be included in the application)
For all enquiries, or if you need support in reaching out to Novo Nordisk members to align and discuss project proposals, please contact either Dorthe Lundsgaard (Senior Alliance Director - Novo Nordisk) or Liz Covey-Crump, (Business Partnerships Manager - University of Oxford).
Overall responsible for the strategic alliance is the Novo Nordisk – Oxford Strategic Alliance Committee (NNOSAC): this committee includes the following members; Professor Sir John Bell, Professor Hugh Watkins, Processor Chas Bountra, Professor Cecilia Lindgren, Professor Marcus Schindler, Dr Lars Fogh Iversen, Professor Bill Haynes.
Responsibility for awarding pump priming grants has been delegated to The Novo Nordisk - Oxford Collaboration Committee (NNOCC). This committee will report to the NNOSAC and includes the following members, Prof Fredrik Karpe, Professor Jeremy Tomlinson, Professor Ana Domingos, Prof Bill Haynes, Dr Carina Ämmälä and Dr Joanna Howson. The NNOCC will meet on a frequent basis, so that approved collaborative activities can be initiated quickly after approval (with an aim of starting within 3 months). NNOCC members can be co-applicants, but will be asked to declare conflicts of interest and refrain from decision making where such conflicts occur.